اخبار و اعلانات

 آمار

تعداد نشریات285
تعداد نشریات سازمان83
تعداد شماره‌ها3,084
تعداد مقالات34,405
تعداد مشاهده مقاله48,460,651
تعداد دریافت فایل اصل مقاله79,100,030
Al-Humairi, R. M. A, Hashim Mohammad, T, Thanoon Ahmed, S, Ad’hiah, A. H. (1401). Systemic Interleukin-6 Response after Intravesical Instillation of Bacillus Calmette-Guérin and Mitomycin C in Superficial Bladder Cancer. سامانه مدیریت نشریات علمی, 78(1), 353-360. doi: 10.22092/ari.2022.358957.2344
R. M. A Al-Humairi; T Hashim Mohammad; S Thanoon Ahmed; A. H Ad’hiah. "Systemic Interleukin-6 Response after Intravesical Instillation of Bacillus Calmette-Guérin and Mitomycin C in Superficial Bladder Cancer". سامانه مدیریت نشریات علمی, 78, 1, 1401, 353-360. doi: 10.22092/ari.2022.358957.2344
Al-Humairi, R. M. A, Hashim Mohammad, T, Thanoon Ahmed, S, Ad’hiah, A. H. (1401). 'Systemic Interleukin-6 Response after Intravesical Instillation of Bacillus Calmette-Guérin and Mitomycin C in Superficial Bladder Cancer', سامانه مدیریت نشریات علمی, 78(1), pp. 353-360. doi: 10.22092/ari.2022.358957.2344
Al-Humairi, R. M. A, Hashim Mohammad, T, Thanoon Ahmed, S, Ad’hiah, A. H. Systemic Interleukin-6 Response after Intravesical Instillation of Bacillus Calmette-Guérin and Mitomycin C in Superficial Bladder Cancer. سامانه مدیریت نشریات علمی, 1401; 78(1): 353-360. doi: 10.22092/ari.2022.358957.2344

Systemic Interleukin-6 Response after Intravesical Instillation of Bacillus Calmette-Guérin and Mitomycin C in Superficial Bladder Cancer

Archives of Razi Institute
مقاله 44، دوره 78، شماره 1، فروردین و اردیبهشت 2023، صفحه 353-360    اصل مقاله (576.54 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2022.358957.2344
نویسندگان
R. M. A Al-Humairi1؛ T Hashim Mohammad1؛ S Thanoon Ahmed1؛ A. H Ad’hiah2
1Department of Biology, College of Science for Women, University of Baghdad, Baghdad, Iraq
2Tropical-Biological Research Unit, College of Science, University of Baghdad, Baghdad, Iraq
چکیده
Interleukin-6 (IL-6) is proposed to play a significant role in pathogenesis of urinary bladder cancer (UBC). This role may be influenced by chemotherapy (mitomycin C; MMC) or immunotherapy (Bacillus Calmette-Guérin; BCG). A case-control study was conducted to determine IL-6 levels in serum of newly diagnosed cases (NDC) of superficial UBC, as well as in patients treated with MMC or BCG intravesical instillation. A total sample of 111 patients (36 NDC, 45 MMC and 30 BCG) was included, as well as a control group of 107 healthy controls (HC). IL-6 was detected by enzyme-linked immunosorbent assay. Results revealed that median levels of IL-6 were significantly elevated in NDC group (15.8 pg/mL; P<0.001) compared to MMC and BCG groups (7.5 and 5.3 pg/mL, respectively) or HC (4.4 pg/mL); while, there were no significant differences between the latter three groups (MMC, BCG and HC). Receiver operating characteristic curve analysis revealed that IL-6 is a very good predictor of UBC in NDC group versus HC (area under the curve=0.885; 95% confidence interval=0.828-0.942; P<0.001; cut-off value=10.5 pg/mL; Youden index=0.62; sensitivity=80.6%; specificity=81.3%). Logistic regression analysis confirmed this significance and IL-6 was associated with a higher risk of UBC (odds ratio=1.18; 95% confidence interval=1.11-1.26; P<0.001). In conclusion, this study indicated that IL-6 level was upregulated in serum of NDC of UBC. Further, IL-6 level was restored to normal levels after intravesical instillation of MMC or BCG.
کلیدواژه‌ها
Urinary bladder cancer؛ Interleukin-6؛ Mitomycin C؛ Bacillus Calmette-Guérin
سایر فایل های مرتبط با مقاله
مراجع
  1. WHO. International Agency for Research on Cancer. Global cancer observatory. 2020. Cancer today Disponível em: https://gco iarc fr/today/home, acedido em. 2021;15.
  2. Chu H, Wang M, Zhang Z. Bladder cancer epidemiology and genetic susceptibility. J Biomed Res. 2013;27(3):170.
  3. Volanis D, Kadiyska T, Galanis A, Delakas D, Logotheti S, Zoumpourlis V. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett. 2010;193(2):131-7.
  4. Thompson PA, Khatami M, Baglole CJ, Sun J, Harris SA, Moon E-Y, et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis. 2015;36(1):232-53.
  5. Nabavizadeh R, Bobrek K, Master VA, editors. Risk stratification for bladder cancer: biomarkers of inflammation and immune activation. Urologic Oncology: Seminars and Original Investigations; 2020: Elsevier.
  6. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204.
  7. Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121.
  8. Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27-41.
  9. Huang X, Pan T, Yan L, Jin T, Zhang R, Chen B, et al. The inflammatory microenvironment and the urinary microbiome in the initiation and progression of bladder cancer. Genes Dis. 2021;8(6):781-97.
  1. Shadpour P, Zamani M, Aghaalikhani N, Rashtchizadeh N. Inflammatory cytokines in bladder cancer. J Cell Physiol. 2019;234(9):14489-99.
  2. Chen M-F, Lin P-Y, Wu C-F, Chen W-C, Wu C-T. IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One. 2013;8(4):e61901.
  3. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther. 2006;8(2):1-6.
  4. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295.
  5. Mauer J, Denson JL, Brüning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 2015;36(2):92-101.
  6. Chonov DC, Ignatova MMK, Ananiev JR, Gulubova MV. IL-6 activities in the tumour microenvironment. Part 1. Open Access Maced J Medical Sci. 2019;7(14):2391.
  7. Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget. 2018;9(51):29820.
  8. Goulet CR, Champagne A, Bernard G, Vandal D, Chabaud S, Pouliot F, et al. Cancer-associated fibroblasts induce epithelial–mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC Cancer. 2019;19(1):1-13.
  9. Silva FM, Videira PA, Ligeiro D, Cabral MG, Sylvester R, Silva FE, et al. Systemic humoral responses of non-muscle-invasive bladder cancer during BCG treatment: less is more. J Cancer Metastatis Treat. 2017;3(1):116-26.
  10. Okamoto M, Hattori K, Oyasu R. Interleukin‐6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer. 1997;72(1):149-54.
  11. Kumari N, Agrawal U, Mishra AK, Kumar A, Vasudeva P, Mohanty NK, et al. Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer. Tumor Biol. 2017;39(4):1010428317697552.
  1. Wu C-T, Lin W-Y, Chen W-C, Chen M-F. Predictive value of CD44 in muscle-invasive bladder cancer and its relationship with IL-6 signaling. Ann Surg Oncol. 2018;25(12):3518-26.
  2. Li C-g, Li M-l, Shu X-h, Liu Y-j, Wu W-s. Antitumor effects of recombinant human Interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis. Cancer Chemother Pharmacol. 2010;66(5):981-6.
  3. Tsui K-H, Wang S-W, Chung L-C, Feng T-H, Lee T-Y, Chang P-L, et al. Mechanisms by which interleukin-6 attenuates cell invasion and tumorigenesis in human bladder carcinoma cells. Biomed Res Int. 2013;2013.
  4. Malmström P-U, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non–muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247-56.
  5. Sato N, Haga J, Anazawa T, Kenjo A, Kimura T, Wada I, et al. Ex vivo pretreatment of islets with mitomycin c: Reduction in immunogenic potential of islets by suppressing secretion of multiple chemotactic factors. Cell Transplant. 2017;26(8):1392-404.
  6. Sinitsky MY, Kutikhin AG, Tsepokina AV, Shishkova DK, Asanov MA, Yuzhalin AE, et al. Mitomycin C induced genotoxic stress in endothelial cells is associated with differential expression of proinflammatory cytokines. Mutation Research/Genetic Toxicol Environ Mutagen. 2020;858:503252.
  7. Tan QL, Zhou CY, Cheng L, Luo M, Liu CP, Xu WX, et al. Immunotherapy of Bacillus Calmette‑Guérin by targeting macrophages against bladder cancer in a NOD/scid IL2Rg‑/‑mouse model. Mol Med Rep. 2020;22(1):362-70.
  8. Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother. 2020;129:110393.
  9. Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15(10):615-25.
آمار
تعداد مشاهده مقاله: 2,558
تعداد دریافت فایل اصل مقاله: 5,998


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب